Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 1411-1420 Newer>

The Motley Fool September 23, 2004 Rich Smith	Insurers vs. Big Pharma The debate over pill-splitting has gone on for some time and will continue to have an effect on the stock prices of whichever side is winning in any given quarter, be it Big Pharma or big insurance and its generic drug allies.
ifeminists September 22, 2004	Fertility Tourism Many aspiring parents dislike the laws that control fertility in the UK and are attracted by the more flexible foreign policies.
The Motley Fool September 20, 2004 W.D. Crotty	Does This Biotech Belong in Bargain Bin? Maxim Pharmaceutical's Ceplene produces disappointing results. Stocks are down more than 50%.
The Motley Fool September 20, 2004 Wherrett & Yelovich	Flamel Shot Down The company's nano product loses some of its shine. The stock fell more than 25% after Bristol-Myers Squibb pulled out of its partnership to develop Basulin.
The Motley Fool September 17, 2004 Rich Smith	The Positive Side of Possis Check on the valuation of the medical device maker's badly wounded stock, based on latest earnings.
Bio-IT World September 16, 2004 John Russell	Sadly, No Free Lunch Drug pricing is legitimately complicated. But what are we getting for all the money being spent on drug development? And who should pick up the tab?
BusinessWeek September 27, 2004 Kerry Capell	How Dublin Keeps Big Pharma Happy By providing cheap yet educated workers and giving tax breaks to big investors, the Irish have turned their country into a major drug manufacturing center.
The Motley Fool September 16, 2004 Alyce Lomax	Depressing Days for Drug Makers? Is black-box labeling of antidepressants going to curtail the mammoth industry?
The Motley Fool September 16, 2004 Dayana Yochim	Here's to Your (Cheaper) Health Care More Americans are looking to Canada for ideas on fixing the health-care crisis.
BusinessWeek September 20, 2004 Amy Barrett	Merck: Who Will Revive The Giant? Earnings and new-drug disappointments have investors worried about succession.
<Older 1411-1420 Newer> Return to current articles.